Windtree Therapeutics, Inc. Capital Expenditures

Capital Expenditures of WINT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Capital Expenditures growth rates and interactive chart. Capital expenditures, commonly known as Capex, are funds used by a company to acquire, upgrade, and maintain physical or intangible assets such as property, buildings, an industrial plant, technology, software or equipment. Capex is often used to undertake new projects or investments by the firm. A company must invest over its lifetime into productive assets to maintain its competitiveness and ensure its survival.


Highlights and Quick Summary

  • Capital Expenditures for the quarter ending June 29, 2020 was $-12 Thousand (a -80.65% decrease compared to previous quarter)
  • Year-over-year quarterly Capital Expenditures decreased by -92.11%
  • Annual Capital Expenditures for 2019 was $-191 Thousand (a -2222.22% decrease from previous year)
  • Annual Capital Expenditures for 2018 was $9 Thousand (a -137.5% decrease from previous year)
  • Annual Capital Expenditures for 2017 was $-24 Thousand (a -90.55% decrease from previous year)
  • Twelve month Capital Expenditures ending June 29, 2020 was $-129 Thousand (a -32.46% decrease compared to previous quarter)
  • Twelve month trailing Capital Expenditures decreased by -42.92% year-over-year
Trailing Capital Expenditures for the last four month:
29 Jun '20 30 Dec '19 29 Sep '19 29 Jun '19
$-129 Thousand $-191 Thousand $-129 Thousand $-226 Thousand
Visit stockrow.com/WINT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Capital Expenditures of Windtree Therapeutics, Inc.

Most recent Capital Expendituresof WINT including historical data for past 10 years.

Interactive Chart of Capital Expenditures of Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. Capital Expenditures for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $-0.01
2019 $-0.06 $0.1 $-0.15 $-0.07 $-0.19
2018 $0.0 $0.0 $0.01 $0.01
2017 $0.0 $0.0 $-0.0 $-0.02 $-0.02
2016 $-0.09 $-0.02 $-0.01 $-0.14 $-0.25
2015 $0.06 $-0.01 $0.21 $-0.45 $-0.19
2014 $-0.1 $0.2 $-0.39 $-0.5 $-0.78
2013 $-0.4 $-0.08 $0.0 $-0.12 $-0.61
2012 $-0.04 $-0.08 $-0.38 $-0.14 $-0.64
2011 $-0.02 $-0.06 $-0.0 $-0.03 $-0.11
2010 $0.0 $-0.03 $-0.02 $-0.06 $-0.1

Business Profile of Windtree Therapeutics, Inc.

Sector: Medical
Industry: Drugs
Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.